Medicenna Therapeutics (TSE:MDNA) has released an update.
Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Medicenna Therapeutics has announced that ASCO retracted the company’s abstract for an oral presentation due to an alleged policy violation, a decision Medicenna disputes. The issue involves distinctions between interim results presented at AACR and the complete data from a Phase 1 study intended for ASCO. Despite this setback, Medicenna plans to reveal the full data set from its ABILITY-1 trial of MDNA11, a promising cancer immunotherapy candidate, in a special virtual event within the next month.
For further insights into TSE:MDNA stock, check out TipRanks’ Stock Analysis page.
